Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: -0.25 (-1.79%)
Spread: 0.50 (3.704%)
Open: 14.00
High: 14.00
Low: 13.75
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Contract Win

20 Jul 2005 08:30

Angle PLC20 July 2005 For Immediate Release 20 July 2005 ANGLE plc Wins Contract With The BioBusiness Alliance of Minnesota ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryis pleased to announce that its US Consulting and Management division has won acontract with The BioBusiness Alliance of Minnesota, worth $200,000, to conducta comprehensive assessment of the state's biobusiness capabilities. The BioBusiness Alliance of Minnesota is an industry-driven, businessdevelopment organisation of representatives from established and emergingMinnesota companies, universities and government. It is devoted to building thebioscience industry, retaining and creating jobs and economic growth, andpositioning Minnesota as a global leader in biobusiness. The Minnesotabiobusiness industry includes many World-class businesses and institutions suchMedtronic, 3M and the Mayo Clinic. The information from the six month assessment, which will conclude in the fourthquarter of 2005, will benchmark Minnesota against other countries and states.The outcome of the process will identify the State's strengths and developmentneeds, and provide recommendations to target specific areas of biobusiness inwhich Minnesota can compete as a global leader. These recommendations willreflect the convergence of technologies, products, and markets that exist in theState, and identify Minnesota's opportunity areas for growth. ANGLE established a Minnesota office in August 2004 in recognition of thesignificant business potential it believes exists in this State. ANGLE waschosen following a rigorous national and international selection process. ANGLEwas selected for their significant experience both in conducting assessments inthe U.S. and internationally, and for their consulting expertise in thetechnology industry. Dr. Gary P. Evans, CEO of ANGLE's US Operations, said: "We are delighted that ANGLE has been selected to deliver this innovative,industry-driven assessment of Minnesota's biobusiness capabilities. We lookforward to working with the BioBusiness Alliance team to take the first step inthe long-term planning and development of a biobusiness strategy for Minnesota." Andrew Newland, Chief Executive of ANGLE plc, said: "This contract is a great example of ANGLE's continuing expansion within theUnited States. The Minnesota region is a prosperous biobusiness arena and thiscontract will position ANGLE alongside some of the biggest names in the market.We expect that Minnesota will emerge as a further key platform for our Venturesbusiness in the US." - ENDS - For further information ANGLE plcAndrew Newland, Chief Executive Tel: +44(0)1483 295830Lisa Smith, Principal Executive, US Operations Tel: +1 301 524 5654 Buchanan Communications Tel: +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to EditorsFounded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. This includes extensiveexpertise in the commercialization of technology, new company formation,investment and corporate finance, Research Park and incubator development andmanagement, and delivery of economic development programs. ANGLE operates fromoffices in the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found onwww.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
1st Jul 20147:00 amRNSNotification of Preliminary Results
29th Apr 20144:30 pmRNSHoldings in Company
8th Apr 20147:00 amRNSIntellectual Property Update
24th Mar 20147:00 amRNSAppointment of Scientific Adviser
17th Mar 20147:00 amRNSParsortix FDA Submission
24th Feb 20147:00 amRNSUse of Parsortix System with Liver Cancer Patients
18th Feb 20147:00 amRNSParsortix Launch at Circulate Conference in Berlin
30th Jan 20147:00 amRNSInterim Results
13th Jan 20147:00 amRNSCambridge Parsortix Laboratory
10th Jan 20147:00 amRNSNotification of Interim Results and Webcast
7th Jan 20147:00 amRNSAppointment of Scientific Adviser
17th Dec 20137:00 amRNSCE Mark Authorisation
13th Dec 20137:00 amRNSRaises £6.2m from Sale of Geomerics
31st Oct 20133:31 pmRNSResult of 2013 Annual General Meeting
9th Oct 20137:00 amRNSAnnual Report and Accounts and Notice of AGM
31st Jul 20137:00 amRNSPreliminary Results
25th Jul 20137:00 amRNSPositive Evaluation of Parsortix System
19th Jul 20137:00 amRNSNotification of Preliminary Results and Webcast
8th Jul 20137:00 amRNSParsortix Colorectal Cancer Validation
29th May 20137:00 amRNSDirector's Share Transfer
28th May 20137:00 amRNSParsortix Manufacturer Appointed
13th May 20137:00 amRNSPARSORTIX CELL HARVESTING
7th May 20137:00 amRNSParsortix Regulatory Approval Update
28th Feb 20137:00 amRNSParsortix Research Product Launch
15th Feb 201310:56 amRNSDirector's share transfer
31st Jan 20137:01 amRNSFundraising and Director's Dealings
31st Jan 20137:00 amRNSInterim Results
16th Jan 20137:00 amRNSNotification of Interim Results and Webcast
14th Jan 20137:00 amRNSParsortix Cell Recovery
7th Jan 20137:00 amRNSAppointment of NED
18th Dec 20127:00 amRNSParsortix Released to Research Partners
10th Dec 20127:00 amRNSBUSINESS UPDATE
18th Oct 20127:00 amRNSAppointment of Scientific Advisers
17th Oct 20123:45 pmRNSHolding(s) in the Company
11th Oct 20123:39 pmRNSResult of 2012 Annual General Meeting
3rd Sep 20127:00 amRNSIncreased Fundraising
1st Aug 20127:00 amRNSIncreased Fundraising
26th Jul 20127:01 amRNSFundraising
26th Jul 20127:00 amRNSPreliminary Results
24th Jul 20127:00 amRNSNotice of Preliminary Results and Conference Call
27th Jun 20127:00 amRNSOffer Unconditional for Novocellus' Partner Origio
7th Jun 20127:00 amRNSUpdate Re Novocellus' Partner ORIGIO A/S
16th May 20127:00 amRNSGeomerics Milestone Payment
30th Apr 20127:00 amRNSParsortix Design Breakthrough
26th Apr 20127:00 amRNSLaunches New Corporate Website
23rd Apr 20127:00 amRNSParsortix Update for Breast Cancer
17th Apr 20127:00 amRNSParsortix Validation for Ovarian Cancer
11th Apr 20127:00 amRNSNovocellus Embryosure® Trial Started
26th Mar 20127:00 amRNSGeomerics Update
15th Mar 20127:00 amRNSParsortix Validation for Colon Cancer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.